Skip to main content
. Author manuscript; available in PMC: 2020 Jun 25.
Published in final edited form as: Clin Cancer Res. 2018 Jul 26;25(2):828–838. doi: 10.1158/1078-0432.CCR-18-0330

Figure 1.

Figure 1.

Expansion of circulating DC-HIL+ MDSCs in patients with metastatic forms of most common solid cancers. A, PBMCs were isolated from blood samples of healthy donors (HD) or patients with metastatic cancer from bladder (BL), breast (BR), colon (CO), kidney (KI), lung (LU), melanoma (ME), pancreatic (PA), or prostate (PR) and examined by flow cytometry for expression of HAL-DR and CD14 (the left dot plots). CD14+ HLA-DRno/lo MDSCs (percentage in total PBMCs shown in a small window) were gated and determined for percentage of DC-HIL+ cells among total MDSCs. Representative data of each malignancy are shown. B, Flow cytometry data of each patient was calculated for percentage of MDSCs in total PBMCs, percentage of DC-HIL positivity in MDSCs, and percentage of DC-HIL+ MDSCs among PBMCs and plotted in a logarithmic or linear scale. Median (percentage) in each cancer type is shown in numerical number and by black lines. Number in the parenthesis indicates the sample size.